We would love to hear your thoughts about our site and services, please take our survey here.
Thank you both!
Please forgive me, but I can't find out how to watch the seminar this afternoon. I am assuming there is a registration link somewhere - could anyone help?
Easy solution - any claim brought by a CMC to FOS that they lose, make them pay the admin fee. At the moment they do little work apart from put together some generic standard paras and market themselves to public on the promise of "what have I got to lose". Putting that at risk for spurious claims would reduce the number!
Right, so ABDX finally put a media post out
https://www.linkedin.com/posts/abingdon-health_london-stock-exchange-london-stock-exchange-activity-7178041844059021313-DZLH?utm_source=share&utm_medium=member_desktop
Liked by Yannick Namia, CEO of our new investment
https://www.linkedin.com/in/yannick-namia/
Thanks Ant, but nobody should look to me. I just post stuff I find, and my own thoughts, much of which may be irrelevant or rubbish!
But in that vein. and in the short term..
IMO this is being held back because the market is concerned about a raise. Regardless of what I think about that, a Director buy would help massively. It would show confidence in the business and indicate that no discounted raise in which they might otherwise participate is on the horizon.
Salistick FDA approval would spark interest from the many out there who think that is our one and only product.
I think we will be launching another test in boots in the pretty near future (weeks according to Crest Medical)
PW - thanks for posting the article, which helps describe the scale of the STI problem.
I haven't been able to shake the thought that somehow these new partners might have come through Senzo. This latest RNS says we have been working with them for 12 months, we announced the Senzo partnership almost 12 months ago to the day, and both the new partners and Senzo are based in the US.
https://www.senzo.com/newsroom/senzo-and-abingdon-health-enter-into-strategic-partnership
So this might also be interesting. Its a blog from Senzo about STI's which again details the scale of the problem and highlights that getting LFT sensitivity levels up when looking at STI conditions has been the main headwind in development. Of course, the whole point of Senzo is to increase sensitivity to PCR levels through its ALF tech.
https://static1.squarespace.com/static/63174674e5302f1a8f9e9dbc/t/659ae1c8fc1f77528ed44d4b/1704649165514/FDX+-+STI%28s%29.pdf
It does worry me that I can't find anything about our new partners, and nor have ABDX put out anything on their media feeds about this news so they're not screaming it from the rooftops - I have written to ABDX to see if they can give me anything more. But if we are looking at an LFT for STI's that meets required sensitivity thresholds then the market looks massive. And of course, by buying into a US based company we are getting a foothold in that jurisdiction.
I think the latter also.
He’s essentially making a growth acquisition from cash flow, without a raise. The fact he feels able to do that, just a week or so after confirming no raise expectation in 2024 and given his laser focus on cash flow break even, strengthens my belief that current revenues and forecasts are more than just robust.
True, assuming the £500k all relates to future cost, and not cost already accrued.
Either Yates has been forced to take equity because there’s no cash, or he wants to take equity. If the latter, then it suggests strongly that he sees real growth potential in the project and expects it to accelerate progress to cash break even and beyond
Don’t really know what to make of this - scattergun thoughts are;
I can find nothing about Devyn LLC, Find Out From Home LLC, or Yannick Namia, which is odd.
The “LLC” suggests they’re US companies. That’s been a real growth area for us.
A £500k stake for 23% values FOFH LLC at over £2m. Not bad for a new unproven enterprise.
Are we investing because we want to, or because they can’t pay the fee? Great if the former - suggests real enthusiasm and potential.
I’m wondering if these new tests might be molecular or based on Senzo ALT tech
Honestly, on the face of it it looks great, but it’s difficult to add colour because there’s little else to go on.
As an aside, it’s interesting they brought the interims forward only to announce a succession of news thereafter.
Yup. We’ve spent the last couple of years rebuilding on a prudent fee for service model, diligently growing our quality customer base. Through 2024 we will see more and more customers commercialising and requiring manufacture. That hopefully will produce a regular and growing annuity income from which further growth can be funded.
This thing sells itself imo. We just need more investors to look under the bonnet, but I’m happy to keep accumulating until they do.
A bit more colour to the ABDX proposition
https://www.abingdonsimplytest.com/own-brand-diagnostics-products-navigating-challenges/
ABDX certainly now pushing this OEM/private label as a new service to retailers
https://www.abingdonsimplytest.com/knowledge-centre/private-own-label-solutions/
This one, from the Co-owner and Director of Crest Medical makes for interesting, and potentially exciting, reading.
“ Delighted to have developed and worked with Abingdon Health plc and Boots UK on these two diagnostic tests … keep an eye out over the next few weeks for the next launch of a revolutionary test!!”
Does he mean another test in conjunction with ABDX - fair bet I think.
https://www.linkedin.com/posts/matthew-courtney-5ab14879_boots-to-sell-its-first-own-brand-self-tests-activity-7176600829678755841-nZVW?utm_source=share&utm_medium=member_desktop
JT - just wondering, but do you think the safety and tolerability results in the AVA6000 trial will mean future trials using the platform could start at higher doses than might otherwise be standard in trial protocols, thus reducing trial timescales?
I hadn’t looked for a while, but seems to me that all of the tests on the AST site have had a branding makeover, and now look like more like proper retail offerings as opposed to medical supplies.
And noticeably, two of the tests now have a very retail oriented instruction for use video - you guessed it, Vitamin D and Iron Deficiency.
Would appreciate anyone's help on something.
As far as I understand it, Boots are effectively going to be white labelling Abingdon Simply Test products. We make them, they buy them from us at a margin, they stick their branded packing around them (or we may do it for them) and they sell them to retail for a margin.
So where does "our partner" Crest Medical fit in? Ae they someone we've made a distribution agreement with, and they are distributing to Boots?
I don't know if it really matters too much apart from the fact that presumably Crest want some piece of the pie.
Thanks
For info - an insight into what industry thinks about the Boots move
https://www.linkedin.com/posts/fernando-ammann-2b697698_healthcare-technology-innovation-activity-7176302251865432064-xh6L?utm_source=share&utm_medium=member_desktop